[go: up one dir, main page]

FR3108032B1 - Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes - Google Patents

Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes Download PDF

Info

Publication number
FR3108032B1
FR3108032B1 FR2002476A FR2002476A FR3108032B1 FR 3108032 B1 FR3108032 B1 FR 3108032B1 FR 2002476 A FR2002476 A FR 2002476A FR 2002476 A FR2002476 A FR 2002476A FR 3108032 B1 FR3108032 B1 FR 3108032B1
Authority
FR
France
Prior art keywords
ligament
muscle
prevention
treatment
physical activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
FR2002476A
Other languages
English (en)
Other versions
FR3108032A1 (fr
Inventor
Guillaume Bermond
Laurent Garçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvamid SA
Original Assignee
Nuvamid SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71661991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR3108032(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nuvamid SA filed Critical Nuvamid SA
Priority to FR2002476A priority Critical patent/FR3108032B1/fr
Priority to US17/910,655 priority patent/US20230149435A1/en
Priority to AU2021235134A priority patent/AU2021235134A1/en
Priority to EP21710504.8A priority patent/EP4117675A1/fr
Priority to JP2022555100A priority patent/JP2023517109A/ja
Priority to PCT/EP2021/056319 priority patent/WO2021180916A1/fr
Priority to CN202180032717.2A priority patent/CN115551516A/zh
Priority to CA3175090A priority patent/CA3175090A1/fr
Publication of FR3108032A1 publication Critical patent/FR3108032A1/fr
Publication of FR3108032B1 publication Critical patent/FR3108032B1/fr
Application granted granted Critical
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention porte sur le nicotinamide mononucléotide, un de ses dérivés pharmaceutiquement acceptables ou un de ses sels pharmaceutiquement acceptables, pour son utilisation dans la prévention et/ou le traitement d’une douleur musculaire, ligamentaire, tendineuse ou leurs combinaisons, induite par l’activité physique ainsi que les compositions le comprenant.
FR2002476A 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes Revoked FR3108032B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2002476A FR3108032B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
JP2022555100A JP2023517109A (ja) 2020-03-12 2021-03-12 身体的活動によって誘発される筋肉、靭帯または腱の痛みを予防および／または治療するためのニコチンアミドモノヌクレオチドまたはその誘導体のいくつかの使用、ならびに対応する組成物
AU2021235134A AU2021235134A1 (en) 2020-03-12 2021-03-12 Use of a nicotinamide mononucleotide or some of its derivatives for the prevention and/or treatment of muscle, ligament or tendon pain induced by physical activity, and corresponding compositions
EP21710504.8A EP4117675A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur musculaire, ligamentaire ou tendineuse induite par l'activite physique, et compositions correspondantes
US17/910,655 US20230149435A1 (en) 2020-03-12 2021-03-12 Use of nmn for the prevention and/or treatment of muscle, ligament or tendon pain induced by physical activity and corresponding compositions
PCT/EP2021/056319 WO2021180916A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur musculaire, ligamentaire ou tendineuse induite par l'activite physique, et compositions correspondantes
CN202180032717.2A CN115551516A (zh) 2020-03-12 2021-03-12 烟酰胺单核苷酸或其某些衍生物用于预防和/或治疗由身体活动引起的肌肉、韧带或肌腱疼痛的用途，以及相应的组合物
CA3175090A CA3175090A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucleotide ou de certains de ses derives pour la prevention et/ou le traitement d'une douleur musculaire, ligamentaire ou tendineuse induite par l' activite physique, et compositions correspondantes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2002476 2020-03-12
FR2002476A FR3108032B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes

Publications (2)

Publication Number Publication Date
FR3108032A1 FR3108032A1 (fr) 2021-09-17
FR3108032B1 true FR3108032B1 (fr) 2024-02-16

Family

ID=71661991

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2002476A Revoked FR3108032B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes

Country Status (8)

Country Link
US (1) US20230149435A1 (fr)
EP (1) EP4117675A1 (fr)
JP (1) JP2023517109A (fr)
CN (1) CN115551516A (fr)
AU (1) AU2021235134A1 (fr)
CA (1) CA3175090A1 (fr)
FR (1) FR3108032B1 (fr)
WO (1) WO2021180916A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4070799A1 (fr) * 2021-04-08 2022-10-12 Nuvamid SA Compositions pour l'amélioration des performances sportives
CN115304655B (zh) * 2021-11-23 2024-11-22 中立安(北京)医药科技有限公司 烟酰胺单核苷类衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US20150283163A1 (en) * 2014-04-04 2015-10-08 Organic Medical Ventures, L.L.C. Muscle treatment composition and method making same
US10485814B2 (en) * 2014-06-06 2019-11-26 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
CA2984379C (fr) * 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Ciblage de nad+ pour traiter la deficience cognitive, les neuropathies et l'inactivite induites par la chimiotherapie et la radiotherapie
US9855289B2 (en) * 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
WO2017079195A1 (fr) 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside et dérivés de nicotinamide mononucléotidique utiles dans les traitements de maladies associées aux mitochondries
WO2017096246A1 (fr) * 2015-12-03 2017-06-08 Temple University-Of The Commonwealth System Of Higher Education Modulation de nad+ et voies métaboliques de nad+ pour le traitement de maladies
WO2016188091A1 (fr) * 2015-12-11 2016-12-01 邦泰生物工程(深圳)有限公司 Utilisation de nicotinamide mononucléotide pour la préparation d'un médicament indiqué pour prévenir ou lutter contre l'athérosclérose et les maladies cardiovasculaires et cérébrovasculaires, et médicament associé
ES2955713T3 (es) * 2016-09-13 2023-12-05 Megumi Tanaka Agente de mejora de la función visual, y método para mejorar la función visual
CN107233352A (zh) * 2017-06-20 2017-10-10 同济大学 烟酰胺腺嘌呤二核苷酸在制备治疗炎性痛药物中的应用
FR3106056B1 (fr) * 2020-01-13 2021-12-17 Nuvamid Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes

Also Published As

Publication number Publication date
US20230149435A1 (en) 2023-05-18
EP4117675A1 (fr) 2023-01-18
AU2021235134A1 (en) 2022-10-06
CN115551516A (zh) 2022-12-30
JP2023517109A (ja) 2023-04-21
CA3175090A1 (fr) 2021-09-16
FR3108032A1 (fr) 2021-09-17
WO2021180916A1 (fr) 2021-09-16

Similar Documents

Publication Publication Date Title
Hundley et al. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study
FR3106056B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes
MX2023007192A (es) Inhibidores de prmt5.
Fietzek et al. Early botulinum toxin treatment for spastic pes equinovarus–a randomized double‐blind placebo‐controlled study
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MX386873B (es) Composiciones farmacéuticas y usos de las mismas para tratar enfermedades cardiovasculares
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
BR0317717A (pt) Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA38648A1 (fr) Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases
BR112021024633A2 (pt) Composições e métodos que usam trigonelina e vitaminas para evitar ou tratar condições ou distúrbios no músculo esquelético
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
BRPI0514736A (pt) inibidores do receptor sigma
EA202192433A1 (ru) Соединения, полезные в терапии вич
FR3108032B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
BR112022015151A2 (pt) Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição
BRPI0406749A (pt) Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
Van Ooteghem et al. Postural motor learning in Parkinson’s disease: The effect of practice on continuous compensatory postural regulation
BR112021021690A2 (pt) Ribosídeos de nicotinamida reduzidos para tratamento/prevenção de doenças do músculo esquelético
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
FR3110836B1 (fr) Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
BR112021024291A2 (pt) Composições e métodos que usam trigonelina e minerais para prevenção ou tratamento de condições ou distúrbios no músculo esquelético
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210917

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

OR Opposition filed

Effective date: 20241119

RT Complete renunciation

Effective date: 20250217

SI End of court proceedings without consequences for the ip right

Effective date: 20250407